Kawasaki disease

Kawasaki disease
Name	Kawasaki disease
Icd10	M30.3
Icd9	446.1
Omim	611539
Eponym	Tomisaku Kawasaki

Kawasaki disease is an acute febrile vasculitis predominantly affecting children and characterized by systemic inflammation of medium-sized arteries, mucocutaneous changes, and lymphadenopathy. First described by pediatrician Tomisaku Kawasaki in Japan in 1967, it is a leading cause of acquired heart disease in children in regions including Japan, the United States, and parts of Europe. Clinical recognition, timely diagnosis, and treatment with intravenous immunoglobulin markedly reduce risk of coronary artery complications.

Signs and symptoms

Acute presentations include persistent fever, conjunctival injection, mucosal changes, and extremity changes often prompting evaluation at centers such as Great Ormond Street Hospital, Boston Children's Hospital, and SickKids Hospital. Typical mucocutaneous findings are erythema of the oral mucosa, fissured lips, and "strawberry tongue" noted in case series from Johns Hopkins Hospital and reports from National Children's Hospital (Vietnam). Other common findings include polymorphous rash, cervical lymphadenopathy often measured during consultations at Mayo Clinic, and swelling or desquamation of the hands and feet documented in cohorts from Seoul National University Hospital. Atypical or incomplete presentations, described in studies from Karolinska Institute, Charité – Universitätsmedizin Berlin, and University of Toronto, may lack the full criteria and complicate recognition. Fever typically lasts more than five days, leading families to seek care from pediatricians associated with institutions like Harvard Medical School and University of California, San Francisco clinics. Clinical scoring systems developed in collaboration with groups from Osaka University, Imperial College London, and University of Sydney help stratify risk.

Cause and pathophysiology

The etiology remains unknown, with hypotheses invoking infectious triggers, immune dysregulation, and genetic susceptibility investigated by researchers at National Institutes of Health, Riken Institute, and Max Planck Society. Epidemiologic clusters resembling outbreaks reported by teams at Centers for Disease Control and Prevention and Public Health England have suggested an environmental or infectious agent. Genetic associations implicating loci such as ITPKC and FCGR2A were identified in genome-wide studies from Kyoto University, Stanford University, and Broad Institute. Pathophysiology involves necrotizing arteritis and panvasculitis of medium-sized arteries, particularly coronary arteries, described in pathology reviews from Johns Hopkins University School of Medicine and Columbia University Irving Medical Center. Immune mechanisms include activation of T cells, B cells, macrophages, and cytokine release (e.g., interleukin pathways) studied at Mount Sinai Hospital, University College London, and University of Tokyo. Superantigen theories compared to agents like Streptococcus pyogenes and Staphylococcus aureus have been explored in publications from University of Cambridge and University of California, Los Angeles.

Diagnosis

Diagnosis is clinical, based on established criteria promulgated by organizations such as the American Heart Association, European Society of Cardiology, and national pediatric societies in Japan. Laboratory testing performed at reference laboratories like those at Mayo Clinic Laboratories and Quest Diagnostics often shows elevated inflammatory markers (e.g., ESR, CRP), thrombocytosis, and sterile pyuria reported in case series from Cincinnati Children's Hospital Medical Center and Children's Hospital of Philadelphia. Echocardiography, the primary imaging modality used by cardiology teams at Stanford Children's Health and Texas Children's Hospital, evaluates coronary artery involvement; findings may prompt consultation with interventional cardiology units at Cleveland Clinic or cardiac surgery teams at Great Ormond Street Hospital. Differential diagnoses considered by clinicians at University of Oxford and Yale New Haven Hospital include toxic shock syndrome linked to Centers for Disease Control and Prevention alerts, measles outbreaks tracked by World Health Organization, and systemic-onset juvenile idiopathic arthritis described in registries at University of Minnesota.

Treatment and management

First-line therapy consists of high-dose intravenous immunoglobulin administered in protocols developed in trials at Kyoto Prefectural University of Medicine, University of Pittsburgh Medical Center, and Vanderbilt University Medical Center, often combined with high-dose aspirin regimens informed by guidance from American Academy of Pediatrics and American Heart Association. Refractory cases may receive corticosteroids, infliximab, or other biologic agents evaluated in clinical trials at Memorial Sloan Kettering Cancer Center, Hospital for Sick Children (Toronto), and Fred Hutchinson Cancer Center. Long-term cardiology follow-up, risk stratification, and secondary prevention strategies are coordinated by centers including Royal Brompton Hospital, National Heart, Lung, and Blood Institute, and Johns Hopkins Hospital Cardiology. Antithrombotic therapy decisions may involve multidisciplinary teams that include experts from European Society of Pediatric Cardiology and American College of Cardiology.

Epidemiology

Incidence is highest in populations of East Asian descent, with robust surveillance data from Japan's national registry, cohort studies from Korea's health system, and epidemiologic analyses from Taiwan's Centers for Disease Control. Annual incidence in Japan is commonly cited in reports by Ministry of Health, Labour and Welfare (Japan), while trends in the United States are monitored by the Centers for Disease Control and Prevention and large pediatric networks such as Pediatric Research in Office Settings (PROS). Seasonal peaks and epidemic patterns have been reported in regional studies from Hokkaido University, University of Melbourne, and University of Cape Town. Age distribution skews toward children under five years, as documented in demographic analyses at Children's National Hospital and Duke University Medical Center.

Complications and prognosis

The major complication is coronary artery aneurysm formation, myocardial dysfunction, and ischemic heart disease seen in long-term follow-up cohorts from Tokyo Women's Medical University, Boston Children's Hospital, and Erasmus Medical Center. Risk of coronary complications is mitigated by early intravenous immunoglobulin as demonstrated in trials from National Institutes of Health and multicenter studies coordinated by Pediatric Heart Network. Late sequelae may require interventional procedures at centers such as St. Jude Children's Research Hospital and Cleveland Clinic Foundation, and long-term outcomes are assessed in registries from Swedish National Board of Health and Welfare and Norwegian Institute of Public Health. Prognosis is generally favorable with prompt treatment, but severe cardiac sequelae can occur, prompting lifelong cardiology surveillance similar to follow-up practices at American Heart Association.

Category:Pediatric diseases